"NCI-H69人小細(xì)胞肺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

【細(xì)胞培養(yǎng)經(jīng)驗分享】啟蒙老師的重要性：一般進實驗室都有師兄師姐帶著做，他們就是你做細(xì)胞的啟蒙老師。他們的操作手法、細(xì)節(jié)、理論講解就成了你操作的準(zhǔn)則，如營養(yǎng)液、細(xì)胞瓶的擺放位置、滅菌處理程序、開蓋手法、細(xì)胞吹打手法等等。要學(xué)會他們的正確操作，在第一次的時候就要重視。像養(yǎng)孩子一樣養(yǎng)細(xì)胞，細(xì)胞有時真的很脆弱，最好每天都去看看它，以防止出現(xiàn)培養(yǎng)箱缺水、缺二氧化碳、停電、溫度不夠等異?，F(xiàn)象，也好及時解決這些意外，避免重復(fù)實驗帶來的更大痛苦。好細(xì)胞要及時保種：細(xì)胞要分批傳代，這樣即使有一批出了問題，還有一批備用的。像后者一般人可能不容易做到。但這是我血的教訓(xùn)，有一次細(xì)胞污染了，全軍覆沒。當(dāng)時可后悔沒有保種。細(xì)胞跟人一樣，不同的細(xì)胞，培養(yǎng)特性是不一樣的。培養(yǎng)過程中要細(xì)細(xì)體會，不同細(xì)胞系使用不同的培養(yǎng)基和血清。

換液周期：每周2-3次

SNU5 Cells;背景說明：該細(xì)胞來源于一名低分化胃癌患者的轉(zhuǎn)移性腹水，１９８７年分離建立。該細(xì)胞表達(dá)CEA和TAG-７２。;傳代方法：２-３天補液一次。;生長特性：多細(xì)胞聚集、懸浮生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：NCI-SNU-C2B細(xì)胞、Hela-Ap-1細(xì)胞、HEK 293-EBNA細(xì)胞

RIN-m5F Cells;背景說明：胰島β細(xì)胞瘤；雄性；NEDH;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCIN87細(xì)胞、CCC-HHM-2細(xì)胞、639V細(xì)胞

JHH7 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：TE354.T細(xì)胞、GM03190細(xì)胞、WERI-Rb-1細(xì)胞

NCI-H69人小細(xì)胞肺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：詳見相關(guān)文獻(xiàn)介紹

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

DSMZ菌株保藏中心成立于1969年，是德國的國家菌種保藏中心。該中心一直致力于細(xì)菌、真菌、質(zhì)粒、抗菌素、人體和動物細(xì)胞、植物病毒等的分類、鑒定和保藏工作。DSMZ菌種保藏中心是歐洲規(guī)模最大的生物資源中心，保藏有動物細(xì)胞500多株。Riken BRC成立于1920年，是英國的國家菌種保藏中心。該中心一直致力于細(xì)菌、真菌、植物病毒等的分類、鑒定和保藏工作。日本Riken BRC(Riken生物資源保藏中心)是全球三大典型培養(yǎng)物收集中心之一。Riken保藏中心提供了很多細(xì)胞系。在世界范圍內(nèi)，這些細(xì)胞系，都在醫(yī)學(xué)、科學(xué)和獸醫(yī)中具有重要意義。Riken生物資源中心支持了各種學(xué)術(shù)、健康、食品和獸醫(yī)機構(gòu)的研究工作，并在世界各地不同組織的微生物實驗室和研究機構(gòu)中使用。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

NCI-H69人小細(xì)胞肺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

MDA-415 Cells;背景說明：這株細(xì)胞表達(dá)WNT７B癌基因。８１６８０８８].帶瘤患者來自巴拉圭，雖然填報的是白人，但細(xì)胞表型存在G６PDＡ型，顯示其屬于混血。細(xì)胞株形成平展延伸的上皮細(xì)胞樣，在電鏡下呈現(xiàn)結(jié)節(jié)，伴隨著延伸的微管和微板。不容易用胰酶消化。;傳代方法：消化５-１０分鐘。１：２。４-５天長滿。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HUVEC細(xì)胞、Mouse INsulinoma 6細(xì)胞、C22 (Clara)細(xì)胞

Y3Ag1.2.3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKLMS1細(xì)胞、SNU16細(xì)胞、MDA MB 361細(xì)胞

HEMCSS Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：８傳代；每周換液３次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：STTG1細(xì)胞、SKCO 1細(xì)胞、RL95細(xì)胞

U138MG Cells;背景說明：星形細(xì)胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HT3細(xì)胞、Y3.AG.1.2.3細(xì)胞、MSTO-211 H細(xì)胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞培養(yǎng)無菌操作步驟和注意事項：１.打開無菌工作臺及凈化室的紫外燈，消毒半小時以上。２.進入凈化室前先關(guān)閉紫外燈，打開超凈臺風(fēng)機，等待３０min以上，以排盡臭氧。３.穿HAO隔離衣，戴HAO口罩，帽子。４.風(fēng)淋２分鐘。５.０.１%水泡手，擦干。６.點燃酒精燈;超凈臺內(nèi)應(yīng)避免放入過多的物品;使用的吸管，滴管，試管，培養(yǎng)瓶等均事先滅菌。７.打開各類瓶蓋前先過火，以固定灰塵;打開的瓶口、試管口過火焰，鑷子使用前應(yīng)經(jīng)火焰燒灼。８.水平式風(fēng)機的超凈臺，應(yīng)使瓶口斜置，應(yīng)盡量避免瓶口敞開直立。９.同一根吸管或滴管不應(yīng)連續(xù)用于幾個不同的細(xì)胞系；吸取培養(yǎng)基的吸管應(yīng)離開培養(yǎng)瓶或試管口０.５cm，避免伸入培養(yǎng)瓶口或試管口；以防止細(xì)胞系的互相混雜污染。１０.漏在培養(yǎng)瓶上或臺上的體，立即用酒精棉球擦凈。１１.操作完畢后恢復(fù)工作臺面。

P-36 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：星形的;相關(guān)產(chǎn)品有：HCT_116細(xì)胞、Chinese Hamster Ovary細(xì)胞、VM-CUB-1細(xì)胞

H-2228 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，每周２-３次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：VB細(xì)胞、KE-39細(xì)胞、KP-N-RT-BM細(xì)胞

H1882 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HONE1細(xì)胞、L cell細(xì)胞、LY細(xì)胞

RD-ES Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：８傳代：每周換液２-３次;生長特性：貼壁和懸浮混合;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：BSC1細(xì)胞、H-810細(xì)胞、OCI-AML-4細(xì)胞

Merwin Plasma Cell tumor-11 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PAI細(xì)胞、SUM 190細(xì)胞、MCF12A細(xì)胞

Rat Chondrosarcoma Swarm Cells;背景說明：軟骨肉瘤；SD;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HL1細(xì)胞、HEK-293A細(xì)胞、MES 23.5細(xì)胞

Hs940-T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：NCI-H2228細(xì)胞、SNU-886細(xì)胞、DMS 79細(xì)胞

SCL-II Cells;背景說明：皮膚鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：C41細(xì)胞、LL/2(LLc1)細(xì)胞、CCFSTTG1細(xì)胞

P3-NS1/1Ag 4.1 Cells;背景說明：這是P３X６３Ag８(ATCCTIB-９)的一個不分泌克隆。Kappa鏈合成了但不分泌。能抗０.１mM８-氮雜鳥嘌呤但不能在HAT培養(yǎng)基中生長。據(jù)報道它是由于缺失了３-酮類固醇還原酶活性的膽固醇營養(yǎng)缺陷型。檢測表明肢骨發(fā)育畸形病毒(鼠痘)陰性。;傳代方法：１：２傳代，３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：SIRC細(xì)胞、VERO C 1008細(xì)胞、H-2122細(xì)胞

BMSCs（mBMSCs） Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U-2OS細(xì)胞、Cloudman S91 melanoma細(xì)胞、BALB/3T3 (clone A31)細(xì)胞

UC-3 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HCFB（HCF）細(xì)胞、NCIH650細(xì)胞、DH-82細(xì)胞

Mono Mac 1 Cells;背景說明：急性單核細(xì)胞白血病；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BHP-10細(xì)胞、KE 37細(xì)胞、Leukemia 1210細(xì)胞

SKNO1 Cells;背景說明：急性髓系白血?。荒行?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-MB-175VII細(xì)胞、HCC-1937細(xì)胞、CT26細(xì)胞

CO115 Cells;背景說明：結(jié)腸腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK.MEL.5細(xì)胞、PECAPJ34細(xì)胞、MADB-106細(xì)胞

NCI-H2066 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次;生長特性：懸浮生長;形態(tài)特性：聚團懸浮;相關(guān)產(chǎn)品有：Panc_08_13細(xì)胞、Hs606T細(xì)胞、3T3細(xì)胞

Leukemia L1210 Cells;背景說明：該細(xì)胞源于用０.２%甲基膽蒽（溶解）涂抹雌性小鼠的皮膚誘發(fā)的腫瘤，鼠痘病毒陰性。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：Normal Rat, August 3, 1983細(xì)胞、NCI.H226細(xì)胞、HCGC細(xì)胞

SW1271 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BT325細(xì)胞、P3X63 AG8-653細(xì)胞、3T3L1細(xì)胞

Abcam HEK293T PBK KO Cells(提供STR鑒定圖譜)

AG11665 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRA060 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XE146 Cells(提供STR鑒定圖譜)

BY00193 Cells(提供STR鑒定圖譜)

CRTDi009-A Cells(提供STR鑒定圖譜)

DA04331 Cells(提供STR鑒定圖譜)

eWT-1323-4 Cells(提供STR鑒定圖譜)

GM07386 Cells(提供STR鑒定圖譜)

RS411 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周２-３次;生長特性：懸浮生長;形態(tài)特性：成淋巴細(xì)胞;相關(guān)產(chǎn)品有：NT2-D1細(xì)胞、LAN-5細(xì)胞、HEK293-FT細(xì)胞

NCI-H69人小細(xì)胞肺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

LS411N Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；每周２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H-510細(xì)胞、GM2219C細(xì)胞、MC-CAR細(xì)胞

E0771 Cells;背景說明：惡性乳腺癌；雌性；C５７BL/６;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Human Corneal Epithelial cells-Transformed細(xì)胞、BC-3-H-I細(xì)胞、kms 11細(xì)胞

JIII Cells;背景說明：單核細(xì)胞白血病;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-MB-468細(xì)胞、LS1034細(xì)胞、3D4/21細(xì)胞

NCI-H676B Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：J82細(xì)胞、CPAE細(xì)胞、A-427細(xì)胞

BT-20 Cells;背景說明：該細(xì)胞１９５８年由E.Y. Lasfargues 和 L. Ozzello 建系，源自一位７４歲白人女性的乳腺癌組織。該細(xì)胞表達(dá)WNT３和WNT７８。TNF alpha抑制該細(xì)胞生長。該細(xì)胞雌激素受體陰性，但表達(dá)５＇外顯子缺失的雌激素mRNA。;傳代方法：１：２—１：４傳代，２—３天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Ramos (RA 1)細(xì)胞、H-1694細(xì)胞、MC-4細(xì)胞

Atg7^(-/-)MEF Cells(提供STR鑒定圖譜)

NCIH2170 Cells;背景說明：該細(xì)胞１９８９年建系，源自一位患有肺鱗狀細(xì)胞癌的男性，該患者不吸煙;傳代方法：１：３—１：６傳代，３—５天換液１次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Karpas-422細(xì)胞、Roswell Park Memorial Institute 8226細(xì)胞、OCILY7細(xì)胞

HCC0202 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：B-CPAP細(xì)胞、HT-29/CX-1細(xì)胞、OV-1063細(xì)胞

Hs68 Cells;背景說明：該細(xì)胞１９６９年由Owens RB建立。;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DMS 114細(xì)胞、OCI-LY-1細(xì)胞、M21細(xì)胞

FCCH1024 Cells;背景說明：該細(xì)胞源自一位１４歲患有T淋巴細(xì)胞白血病男性的外周血;傳代方法：保持細(xì)胞密度在３—９×１０５cells/ml之間，１：５—１：１０傳代，每周換液２—３次;生長特性：懸浮生長;形態(tài)特性：圓形，單個或呈片;相關(guān)產(chǎn)品有：751-NA細(xì)胞、KBM-7細(xì)胞、Emory University-3細(xì)胞

H810 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：６傳代,每周２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：C-6細(xì)胞、L-929細(xì)胞、SW 756細(xì)胞

KM12SM Cells;背景說明：結(jié)腸癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OV90細(xì)胞、16-HBEo細(xì)胞、SW 948細(xì)胞

HGC-27 Cells;背景說明：未分化胃癌，能分泌粘液素。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：FLS細(xì)胞、H510細(xì)胞、Roswell Park Memorial Institute 7951細(xì)胞

T98 G Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：按１：３傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Colon38細(xì)胞、MMQ細(xì)胞、32D.cl3細(xì)胞

HAP1 ATF6 (-) 2 Cells(提供STR鑒定圖譜)

HAP1 SLC48A1 (-) Cells(提供STR鑒定圖譜)

PC-2 [Human pancreatic carcinoma] Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SHSY5Y細(xì)胞、QBI-293A細(xì)胞、NCIH1623細(xì)胞

M059K Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：６-１：８傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：NMCG1細(xì)胞、C-Lu65細(xì)胞、M07e細(xì)胞

OPM2 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KP-N-YN細(xì)胞、SKRC 39細(xì)胞、RSC-364細(xì)胞

HA Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HOS/MNNG細(xì)胞、UCW 100細(xì)胞、SCC VII細(xì)胞

NCI-H740 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LA-N-6細(xì)胞、AM細(xì)胞、Panc_08_13細(xì)胞

CoCL2 Cells;背景說明：結(jié)腸腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HBL-1 [Human diffuse large B-cell lymphoma]細(xì)胞、143BTK-細(xì)胞、J774A.1細(xì)胞

L 1210 Cells;背景說明：該細(xì)胞源于用０.２%甲基膽蒽（溶解）涂抹雌性小鼠的皮膚誘發(fā)的腫瘤，鼠痘病毒陰性。;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：BHP10-3細(xì)胞、NCI-SNU-5細(xì)胞、NCI-H2073細(xì)胞

H1651 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：OVSAHO細(xì)胞、LC-2-Ad細(xì)胞、SkChA1細(xì)胞

iBMK BIM+/+ A.Hras-B Cells(提供STR鑒定圖譜)

Lis18_Connexin2 Cells(提供STR鑒定圖譜)

NCCSEDi001-A Cells(提供STR鑒定圖譜)

PathHunter CHO-K1 EDG1 beta-arrestin Cells(提供STR鑒定圖譜)

S16Y Cells(提供STR鑒定圖譜)

Ubigene HeLa DDX39B KO Cells(提供STR鑒定圖譜)

WY005 Cells(提供STR鑒定圖譜)

HAP1 TET1 (-) TET2 (-) 2 Cells(提供STR鑒定圖譜)

HMC3 Cells;背景說明：小膠質(zhì)細(xì)胞；SV４０轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：LC-1Sq細(xì)胞、CG-4細(xì)胞、HConEpic細(xì)胞

G361 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：EBNA-293細(xì)胞、H-1755細(xì)胞、Ly10細(xì)胞

LS 1034 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３傳代，每周２-３次;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：MNNG-HOS (TE 85, clone F-5)細(xì)胞、LY細(xì)胞、OVCA 433細(xì)胞

BT-325 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SNU601細(xì)胞、Merwin Plasma Cell tumor-11細(xì)胞、NCI-H87細(xì)胞

RGM-1 Cells;背景說明：胃黏膜；上皮細(xì)胞；自發(fā)永生；Wistar;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RCC_7860細(xì)胞、MDA436細(xì)胞、HCC-1143細(xì)胞

RGM-1 Cells;背景說明：胃黏膜；上皮細(xì)胞；自發(fā)永生；Wistar;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RCC_7860細(xì)胞、MDA436細(xì)胞、HCC-1143細(xì)胞

HS578T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-468細(xì)胞、EAhy 926細(xì)胞、LA-N-6(OAN)細(xì)胞

LS-174 Cells;背景說明：LS １７４T是LS １８０ (ATCC CL １８７)結(jié)腸腺癌細(xì)胞株的胰蛋白酶化變種。 它比親本更易傳代，象LS １８０一樣生成大量的癌胚抗原(CEA)。 電鏡研究表明有豐富的微絲和細(xì)胞質(zhì)粘液素液泡。 直腸抗原３陽性。 p５３抗原表達(dá)陰性，但mRNA表達(dá)陽性。 與ATCC CL-１８７來源于同一個腫瘤。LS １７４T細(xì)胞角蛋白染色陽性。 癌基因c-myc, N-myc, H-ras, N-ras, Myb, 和 fos的表達(dá)呈陽性。 癌基因k-ras和sis的表達(dá)未做檢測。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：OLN-93細(xì)胞、NCI-H1703細(xì)胞、HCC-2279細(xì)胞

KM H-2 Cells;背景說明：霍奇金淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H1838細(xì)胞、Kit 225細(xì)胞、AZ521細(xì)胞

58F Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BNL CL2細(xì)胞、H1395細(xì)胞、NCI-H2135細(xì)胞

RGCs Cells;背景說明：視網(wǎng)膜；神經(jīng)節(jié) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-MES-1細(xì)胞、C81-61細(xì)胞、3T6 Swiss Albino細(xì)胞

RGCs Cells;背景說明：視網(wǎng)膜；神經(jīng)節(jié) Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-MES-1細(xì)胞、C81-61細(xì)胞、3T6 Swiss Albino細(xì)胞

SKML-28 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：星形的;相關(guān)產(chǎn)品有：CT26.CL25細(xì)胞、TE32細(xì)胞、PG13細(xì)胞

Hs 578T Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-N-AS細(xì)胞、F98細(xì)胞、WM 239-A細(xì)胞

NCI-H1395 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；５-６天傳代一次。;生長特性：貼壁生長;形態(tài)特性：上皮樣；多角形;相關(guān)產(chǎn)品有：NCI-HUT-520細(xì)胞、MESSA細(xì)胞、H-748細(xì)胞

TK-1D Cells(提供STR鑒定圖譜)

COLO 320 HSR Cells;背景說明：該細(xì)胞１９８４年建系，源自一位３３歲患有大腸腺癌男性經(jīng)５-fu治療后的腹水。;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：半貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DR2R1610細(xì)胞、E0771細(xì)胞、H-498細(xì)胞

OVISE Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：５ x １０^４ cells/ml;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HCC1954BL細(xì)胞、H2087細(xì)胞、HM細(xì)胞

NCI H548 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC 38細(xì)胞、MDAMB175VII細(xì)胞、AQ-Mel細(xì)胞

QBC-939 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RC13細(xì)胞、TSUpr1細(xì)胞、P31/Fujioka細(xì)胞

Mink Lung Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H1915細(xì)胞、HCC-44細(xì)胞、LNCaP clone FGC細(xì)胞

WM239A Cells;背景說明：黑色素瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PC-3M-IE8細(xì)胞、OVCAR420細(xì)胞、TCMK1細(xì)胞

NCI-H69人小細(xì)胞肺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

SKNAS Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：５-１：１０傳代；每周換液２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SNK-6細(xì)胞、Super Tube細(xì)胞、NIH:OVCAR4細(xì)胞

NCI-H841 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：５傳代，;生長特性：混合型生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BNL.1ME A.7R.1細(xì)胞、NOZAWA細(xì)胞、Colo16細(xì)胞

DMS153 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PL-9細(xì)胞、NCI-H1819細(xì)胞、SK-Mel1細(xì)胞

HCS-2/8 Cells;背景說明：軟骨肉瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：293 c18細(xì)胞、P3 (Jiyoye)細(xì)胞、MNNG-HOS (TE 85, clone F-5)細(xì)胞

A-72 Cells;背景說明：癌細(xì)胞；金毛獵犬;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-157細(xì)胞、NCI-H220細(xì)胞、BT 549細(xì)胞

NCIH2228 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，每周２-３次。;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KCL-22細(xì)胞、FHL-124細(xì)胞、hEEC細(xì)胞

SNU-C2A Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每周兩次換液;生長特性：松散附著、多單元的聚合;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HNE1細(xì)胞、Panc02.03細(xì)胞、801-D細(xì)胞

HBZY-1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HT(H9)細(xì)胞、CHL1細(xì)胞、Centre Antoine Lacassagne-39細(xì)胞

BayGenomics ES cell line RRO390 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHC001 Cells(提供STR鑒定圖譜)

HBS-22 Cells(提供STR鑒定圖譜)

PCRP-BHLHA9-1D1 Cells(提供STR鑒定圖譜)

BE26 Cells(提供STR鑒定圖譜)

HPS0214 Cells(提供STR鑒定圖譜)

" "PubMed=6148444; DOI=10.1093/jnci/73.4.801

Morstyn G., Russo A., Carney D.N., Karawya E., Wilson S.H. Jr., Mitchell J.B.

Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines.

J. Natl. Cancer Inst. 73:801-807(1984)

PubMed=6713399

Rosen S.T., Mulshine J.L., Cuttitta F., Fedorko J., Carney D.N., Gazdar A.F., Minna J.D.

Analysis of human small cell lung cancer differentiation antigens using a panel of rat monoclonal antibodies.

Cancer Res. 44:2052-2061(1984)

PubMed=2985257

Carney D.N., Gazdar A.F., Bepler G., Guccion J.G., Marangos P.J., Moody T.W., Zweig M.H., Minna J.D.

Establishment and identification of small cell lung cancer cell lines having classic and variant features.

Cancer Res. 45:2913-2923(1985)

PubMed=2985258

Gazdar A.F., Carney D.N., Nau M.M., Minna J.D.

Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties.

Cancer Res. 45:2924-2930(1985)

PubMed=2986243; DOI=10.1007/978-3-642-82372-5_4

Whang-Peng J., Lee E.C.

Cytogenetics of human small cell lung cancer.

Recent Results Cancer Res. 97:37-46(1985)

PubMed=3034934; DOI=10.1002/jcb.240330405

Ibson J.M., Waters J.J., Twentyman P.R., Bleehen N.M., Rabbitts P.H.

Oncogene amplification and chromosomal abnormalities in small cell lung cancer.

J. Cell. Biochem. 33:267-288(1987)

PubMed=2473086; DOI=10.1242/jcs.91.1.91

Broers J.L.V., Rot M.K., Oostendorp T., Bepler G., de Leij L.F.M.H., Carney D.N., Vooijs G.P., Ramaekers F.C.S.

Spontaneous changes in intermediate filament protein expression patterns in lung cancer cell lines.

J. Cell Sci. 91:91-108(1988)

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=2574988; DOI=10.1038/bjc.1989.376; PMCID=PMC2247271

Jensen P.B., Vindelov L.L., Roed H., Demant E.J.F., Sehested M., Skovsgaard T., Hansen H.H.

In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).

Br. J. Cancer 60:838-844(1989)

PubMed=2594029; DOI=10.1056/NEJM198912213212501

Yandell D.W., Campbell T.A., Dayton S.H., Petersen R., Walton D., Little J.B., McConkie-Rosell A., Buckley E.G., Dryja T.P.

Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling.

N. Engl. J. Med. 321:1689-1695(1989)

PubMed=2388294; DOI=10.1093/jnci/82.17.1420

McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C., Adelberg S., Czerwinski M.J., McMahon N.A., Eggleston J.C., Boyd M.R.

Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

J. Natl. Cancer Inst. 82:1420-1426(1990)

PubMed=1662924

Khan M.Z., Freshney R.I., Murray A.M.B., Merry S., Plumb J.A., McNicol A.M.

Identification and characterisation in vitro of cells with a non-SCLC cell-like phenotype derived from a continuous SCLC cell line.

Anticancer Res. 11:1687-1695(1991)

PubMed=1845952; DOI=10.1002/1097-0142(19910201)67:3<619::AID-CNCR2820670317>3.0.CO;2-Y

Broers J.L.V., Mijnheere E.P., Rot M.K., Schaart G., Sijlmans A., Boerman O.C., Ramaekers F.C.S.

Novel antigens characteristic of neuroendocrine malignancies.

Cancer 67:619-633(1991)

PubMed=1847845; DOI=10.1007/BF00685110

Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T., Saijo N.

Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.

Cancer Chemother. Pharmacol. 27:263-270(1991)

PubMed=7903701; DOI=10.1093/jnci/86.2.110

Barrand M.A., Heppell-Parton A.C., Wright K.A., Rabbitts P.H., Twentyman P.R.

A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistant cells and its relationship to the MRP gene.

J. Natl. Cancer Inst. 86:110-117(1994)

PubMed=8263009; DOI=10.1007/BF01202192

Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.

Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.

J. Cancer Res. Clin. Oncol. 120:143-148(1994)

PubMed=7736387; DOI=10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q

Campling B.G., Sarda I.R., Baer K.A., Pang S.C., Baker H.M., Lofters W.S., Flynn T.G.

Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer.

Cancer 75:2442-2451(1995)

PubMed=8626706; DOI=10.1074/jbc.271.19.11477

Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F.

Insulin-like growth factor expression in human cancer cell lines.

J. Biol. Chem. 271:11477-11483(1996)

PubMed=8712684

Khan M.Z., McNicol A.M., Freshney R.I.

Tumorigenicity, invasion and metastasis of the small cell lung cancer cell line NCI-H69 and two derivative lines MOG-H69V and MOG-H69VZ.

Anticancer Res. 16:1659-1669(1996)

PubMed=8784480; DOI=10.1159/000227600

Shinohara A., Shimizu E., Takada M., Sone S.

Lack of c-mpl proto-oncogene transcripts and growth-stimulatory effects of thrombopoietin on human small cell lung cancer cell lines.

Oncology 53:426-434(1996)

PubMed=8806092; DOI=10.1002/jcb.240630505

Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

NCI-Navy Medical Oncology Branch cell line data base.

J. Cell. Biochem. Suppl. 24:32-91(1996)

PubMed=8806103; DOI=10.1002/jcb.240630516

Johnson B.E., Russell E., Simmons A.M., Phelps R.M., Steinberg S.M., Ihde D.C., Gazdar A.F.

MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer.

J. Cell. Biochem. Suppl. 24:210-217(1996)

PubMed=9212023; DOI=10.1016/S0360-3016(97)00245-9

Krarup M., Poulsen H.S., Spang-Thomsen M.

Cellular radiosensitivity of small-cell lung cancer cell lines.

Int. J. Radiat. Oncol. Biol. Phys. 38:191-196(1997)

PubMed=9413215

Yamane H., Kiura K., Tabata M., Bessho A., Tsuchida T., Motoda K., Hiraki A., Ueoka H., Harada M.

Small cell lung cancer can express CD34 antigen.

Anticancer Res. 17:3627-3632(1997)

PubMed=9815546

Campling B.G., Young L.C., Baer K.A., Lam Y.-M., Deeley R.G., Cole S.P.C., Gerlach J.H.

Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.

Clin. Cancer Res. 3:115-122(1997)

PubMed=9559344; DOI=10.1002/(SICI)1098-2264(199804)21:4<326::AID-GCC6>3.0.CO;2-0

Mulligan L.M., Timmer T., Ivanchuk S.M., Campling B.G., Young L.C., Rabbitts P.H., Sundaresan V., Hofstra R.M.W., Eng C.

Investigation of the genes for RET and its ligand complex, GDNF/GFR alpha-I, in small cell lung carcinoma.

Genes Chromosomes Cancer 21:326-332(1998)

PubMed=9744504; DOI=10.1038/bjc.1998.553; PMCID=PMC2063065

Damstrup L., Voldborg B.G.R., Spang-Thomsen M., Brunner N., Poulsen H.S.

In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.

Br. J. Cancer 78:631-640(1998)

PubMed=10037197

Tang X.X., Brodeur G.M., Campling B.G., Ikegaki N.

Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma.

Clin. Cancer Res. 5:455-460(1999)

PubMed=10358721; DOI=10.18926/AMO/31626

Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K., Kohara H., Harada M.

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Acta Med. Okayama 53:67-75(1999)

PubMed=10536175; DOI=10.3892/ijo.15.5.927

Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.

Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.

Int. J. Oncol. 15:927-934(1999)

PubMed=11005564; DOI=10.1038/sj.neo.7900094; PMCID=PMC1550293

Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J.

Mutation and expression of the DCC gene in human lung cancer.

Neoplasia 2:300-305(2000)

PubMed=11030152; DOI=10.1038/sj.onc.1203815

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Oncogene 19:4632-4639(2000)

PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=12569360; DOI=10.1038/sj.onc.1206106

Funakoshi T., Tachibana I., Hoshida Y., Kimura H., Takeda Y., Kijima T., Nishino K., Goto H., Yoneda T., Kumagai T., Osaki T., Hayashi S., Aozasa K., Kawase I.

Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer.

Oncogene 22:674-687(2003)

PubMed=17426248; DOI=10.1158/1541-7786.MCR-06-0367

Olejniczak E.T., Van Sant C., Anderson M.G., Wang G., Tahir S.K., Sauter G., Lesniewski R., Semizarov D.

Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains.

Mol. Cancer Res. 5:331-339(2007)

PubMed=19394761; DOI=10.1016/j.canlet.2009.03.038

Shibata T., Kokubu A., Tsuta K., Hirohashi S.

Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.

Cancer Lett. 283:203-211(2009)

PubMed=19446745; DOI=10.1016/j.cancergencyto.2009.01.016

Salido M., Arriola E., Carracedo A., Canadas I., Rovira A., Espinet B., Rojo F., Arumi-Uria M., Serrano S., Albanell J., Sole F.

Cytogenetic characterization of NCI-H69 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping.

Cancer Genet. Cytogenet. 191:97-101(2009)

PubMed=19472407; DOI=10.1002/humu.21028; PMCID=PMC2900846

Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

A gene-alteration profile of human lung cancer cell lines.

Hum. Mutat. 30:1199-1206(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x; PMCID=PMC11158680

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Cancer Sci. 101:1891-1896(2010)

PubMed=20615970; DOI=10.1073/pnas.1008132107; PMCID=PMC2919980

Voortman J., Lee J.-H., Killian J.K., Suuriniemi M., Wang Y.-H., Lucchi M., Smith W.I. Jr., Meltzer P.S., Wang Y.-S., Giaccone G.

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

Proc. Natl. Acad. Sci. U.S.A. 107:13040-13045(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112; PMCID=PMC3567922

Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J.S., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Cancer Discov. 2:798-811(2012)

PubMed=23716474; DOI=10.1002/gcc.22076; PMCID=PMC3806277

Iwakawa R., Takenaka M., Kohno T., Shimada Y., Totoki Y., Shibata T., Tsuta K., Nishikawa R., Noguchi M., Sato-Otsubo A., Ogawa S., Yokota J.

Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.

Genes Chromosomes Cancer 52:802-816(2013)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=30038707; DOI=10.18632/oncotarget.25642; PMCID=PMC6049873

Du L.-Q., Zhao Z.-Z., Suraokar M.B., Shelton S.S., Ma X.-Y., Hsiao T.-H., Minna J.D., Wistuba I.I., Pertsemlidis A.

LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer.

Oncotarget 9:29601-29618(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)"